Pivotal data cement use of Incyte, Novartis' ruxolitinib in difficult-to-treat graft-versus-host disease
Allogeneic stem-cell transplants, in which patients are given stem cells harvested from a donor to replenish depleted supplies caused by radiation treatment or high doses of chemotherapy, are on the rise. But despite standard steroid therapy, acute graft-versus-host disease (GVHD), where the donor T cells attack host tissue, occurs in about half the patients and little progress has been made in developing an effective strategy to combat the life-threatening complication in the past three decades.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
